Westlake Village-based Arcutis’ losses continue to mount, but in the third quarter of 2022 it recorded product revenue for the first time in its history. Arcutis, a biotechnology company focused on treating skin diseases, launched its first product, Zoryve, in August. Zoryve is a cream focused on the treatment of plaque psoriasis in adolescents and…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
